PURPOSE: To compare the ultrasound (US) and pulse shear wave elastography (pSWE, Elast PQ®) methods with transient elastography (TE), clinical scores and laboratory tests, during the follow-up of HCV patients receiving direct-acting antiviral drugs (DAA). METHODS: Our prospective study from June 2016 to December 2017 included 22 consecutively enrolled HCV-positive patients (59.7 ± 12.3 years, 11 male) which were subjected to antiviral therapy. All patients underwent B-mode ultrasound, color-Doppler, pSWE and TE five times: before therapy (T0), at the end of therapy (post-Tx), and at 12, 24, 48 weeks post-therapy. The liver stiffness (LS) values obtained with pSWE and TE and the data coming from US assessment and clinical evaluation were compared. RESULTS: We obtained a statistically significant reduction of LS values (kPa) measured by pSWE, between T0 (14.3 ± 9.3), post-Tx (11.8 ± 10.5), 12 weeks (7.5 ± 3.3), 24 weeks (8 ± 3.8) and 48 weeks (8.5 ± 4.6) (p = 0.02). The reduction of kPa measured by TE was not significant between T0 (14.7 ± 9.3), post-Tx (12 ± 9.5), 12 weeks (11.6 ± 7.7), 24 weeks (10.3 ± 6) and 48 weeks (10.8 ± 7.5) (p > 0.05). Multivariate baseline analysis showed significant independent association among measurement of TE stiffness with cirrhosis, type of vein hepatic flow and showed significant independent association between delta-pSWE measurement (difference between stiffness measurements at the baseline and 12 months after treatment) with staging of fibrosis (p = 0.006) and sustained virologic response after 12 weeks of treatment (SVR12, p = 0.017). CONCLUSION: The pSWE method has shown better ability than TE to identify a reduction in LS. Therefore, pSWE allow to evaluate stiffness reduction in HCV patient during DAA treatment follow-up, which is related to SVR12.
PURPOSE: To compare the ultrasound (US) and pulse shear wave elastography (pSWE, Elast PQ®) methods with transient elastography (TE), clinical scores and laboratory tests, during the follow-up of HCV patients receiving direct-acting antiviral drugs (DAA). METHODS: Our prospective study from June 2016 to December 2017 included 22 consecutively enrolled HCV-positive patients (59.7 ± 12.3 years, 11 male) which were subjected to antiviral therapy. All patients underwent B-mode ultrasound, color-Doppler, pSWE and TE five times: before therapy (T0), at the end of therapy (post-Tx), and at 12, 24, 48 weeks post-therapy. The liver stiffness (LS) values obtained with pSWE and TE and the data coming from US assessment and clinical evaluation were compared. RESULTS: We obtained a statistically significant reduction of LS values (kPa) measured by pSWE, between T0 (14.3 ± 9.3), post-Tx (11.8 ± 10.5), 12 weeks (7.5 ± 3.3), 24 weeks (8 ± 3.8) and 48 weeks (8.5 ± 4.6) (p = 0.02). The reduction of kPa measured by TE was not significant between T0 (14.7 ± 9.3), post-Tx (12 ± 9.5), 12 weeks (11.6 ± 7.7), 24 weeks (10.3 ± 6) and 48 weeks (10.8 ± 7.5) (p > 0.05). Multivariate baseline analysis showed significant independent association among measurement of TE stiffness with cirrhosis, type of vein hepatic flow and showed significant independent association between delta-pSWE measurement (difference between stiffness measurements at the baseline and 12 months after treatment) with staging of fibrosis (p = 0.006) and sustained virologic response after 12 weeks of treatment (SVR12, p = 0.017). CONCLUSION: The pSWE method has shown better ability than TE to identify a reduction in LS. Therefore, pSWE allow to evaluate stiffness reduction in HCV patient during DAA treatment follow-up, which is related to SVR12.
Authors: Vincenza Calvaruso; Irene Cacciola; Anna Licata; Salvatore Madonia; Rosa Benigno; Salvatore Petta; Fabrizio Bronte; Elisabetta Conte; Giuseppe Malizia; Gaetano Bertino; Marco Distefano; Arturo Montineri; Antonio Digiacomo; Giuseppe Alaimo; Bruno Cacopardo; Antonio Davì; Luigi Guarneri; Ignazio Scalisi; Pietro Colletti; Fabio Cartabellotta; Vincenzo Portelli; Tullio Prestileo; Alfonso Averna; Carmelo Iacobello; Lorenzo Mondello; Gaetano Scifo; Maurizio Russello; Giovanni Squadrito; Giovanni Raimondo; Calogero Cammà; Antonio Craxì; Vito Di Marco Journal: Am J Gastroenterol Date: 2019-08 Impact factor: 10.864
Authors: Cristina Felicani; Chiara De Molo; Horia Stefanescu; Fabio Conti; Elena Mazzotta; Veronica Gabusi; Elena Nardi; Antonio Maria Morselli-Labate; Pietro Andreone; Carla Serra Journal: J Ultrasound Date: 2018-05-22
Authors: A Erman; A Sathya; A Nam; J M Bielecki; J J Feld; H-H Thein; W W L Wong; P Grootendorst; M D Krahn Journal: J Viral Hepat Date: 2018-01-24 Impact factor: 3.728
Authors: M Fraquelli; A Baccarin; G Casazza; C B Conti; M Giunta; S Massironi; F Invernizzi; M F Donato; M Maggioni; A Aghemo; D Conte; M Colombo Journal: Aliment Pharmacol Ther Date: 2016-06-30 Impact factor: 8.171
Authors: Sweta Chekuri; Jillian Nickerson; Kian Bichoupan; Roberta Sefcik; Kamini Doobay; Sanders Chang; David DelBello; Alyson Harty; Douglas T Dieterich; Ponni V Perumalswami; Andrea D Branch Journal: PLoS One Date: 2016-07-21 Impact factor: 3.240
Authors: Igino Simonetti; Federico Bruno; Roberta Fusco; Carmen Cutolo; Sergio Venanzio Setola; Renato Patrone; Carlo Masciocchi; Pierpaolo Palumbo; Francesco Arrigoni; Carmine Picone; Andrea Belli; Roberta Grassi; Francesca Grassi; Antonio Barile; Francesco Izzo; Antonella Petrillo; Vincenza Granata Journal: J Pers Med Date: 2022-07-16
Authors: Omar A Saldarriaga; Bradley Dye; Judy Pham; Timothy G Wanninger; Daniel Millian; Michael Kueht; Benjamin Freiberg; Netanya Utay; Heather L Stevenson Journal: Sci Rep Date: 2021-07-15 Impact factor: 4.379